DENALI THERAPEUTICS IN

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

25 يناير 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

09 يناير 2023 07:00:44 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

05 ديسمبر 2022 06:00:41 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

03 نوفمبر 2022 15:01:44 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN

01 نوفمبر 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

24 أكتوبر 2022 15:30:04 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock

19 أكتوبر 2022 20:19:42 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Proposed Offering of Common Stock

18 أكتوبر 2022 15:40:50 بحسب Nasdaq GlobeNewswire

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

03 أكتوبر 2022 07:00:39 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022

31 أغسطس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

08 أغسطس 2022 15:01:01 بحسب Nasdaq GlobeNewswire

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

31 مايو 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

05 مايو 2022 15:01:01 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi

02 مايو 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions to Denali Board of Directors

15 مارس 2022 15:30:28 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN)

09 مارس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

28 فبراير 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial

10 فبراير 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors

07 فبراير 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on DNL310 (ETV:IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™

01 فبراير 2022 08:00:01 بحسب Nasdaq GlobeNewswire